跳至主要内容
临床试验/EUCTR2012-002002-46-AT
EUCTR2012-002002-46-AT进行中(未招募)1 期

A phase III, randomized, controlled clinical pilot trial of lateral ridge augmentation using autogenous bone blocks or xenogenic bone block grafts loaded with recombinant human bone morphogenic protein 2 - BMP2

niversitätsklinik für Zahn-, Mund- und Kieferheilkunde, Med Uni Graz, Department für zahnärztliche Chirurgie0 个研究点目标入组 24 人开始时间: 2013年4月4日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
24

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

入选标准

  • patients requiring implant therapy for the reconstruction of 1 to 4 missing teeth
  • patients revealing insufficient bone volume for implant placement
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 8
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 4

排除标准

  • severe diseases
  • medications with a contraindication for implant therapy
  • insufficent bone volume for harvesting a autogenous block
  • pregnancy and breast feeding

研究者

发起方
niversitätsklinik für Zahn-, Mund- und Kieferheilkunde, Med Uni Graz, Department für zahnärztliche Chirurgie

相似试验

进行中(未招募)
1 期
Phase III Randomized Controlled Trial of Pembrolizumab with or without Chemo vs Chemo in Advanced Urothelial CarcinomaAdvanced or Metastatic Urothelial CarcinomaMedDRA version: 20.0Level: LLTClassification code 10064467Term: Urothelial carcinomaSystem Organ Class: 100000004864
EUCTR2015-005731-41-IEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.990
已完成
3 期
A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemotherapy versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Carcinomabladder cancer
NL-OMON45288Merck Sharp & Dohme (MSD)20
进行中(未招募)
1 期
Phase III Randomized Controlled Trial of Pembrolizumab with or without Chemo vs Chemo in Advanced Urothelial CarcinomaAdvanced or Metastatic Urothelial CarcinomaMedDRA version: 19.0Level: LLTClassification code 10064467Term: Urothelial carcinomaSystem Organ Class: 100000004864
EUCTR2015-005731-41-ESMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.990
进行中(未招募)
1 期
Phase III Randomized Controlled Trial of Pembrolizumab with or without Chemo vs Chemo in Advanced Urothelial CarcinomaAdvanced or Metastatic Urothelial CarcinomaMedDRA version: 20.0Level: LLTClassification code 10064467Term: Urothelial carcinomaSystem Organ Class: 100000004864
EUCTR2015-005731-41-GBMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.990
进行中(未招募)
1 期
Phase III Randomized Controlled Trial of Pembrolizumab with or without Chemo vs Chemo in Advanced Urothelial CarcinomaAdvanced or Metastatic Urothelial CarcinomaMedDRA version: 20.0Level: LLTClassification code 10064467Term: Urothelial carcinomaSystem Organ Class: 100000004864
EUCTR2015-005731-41-BEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.990